Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of YHP1906 (Apixaban) vs YHR1902 in Healthy Volunteers
NCT04316065Phase 1Completed
- Sponsor
- Yuhan
- Start
- Apr 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of YHP1906 in thromboembolism (2 arms), sponsored by Yuhan. Primary endpoints: Area under the plasma drug concentration-time curve [AUCt] and Maximum plasma concentration [Cmax]. Started Apr 2020; status: completed.
02
Drugs
YHP1906
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04316065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316065.